Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michela Peroni"'
Autor:
Arianna Catenacci, Michela Peroni, Fabian Gievers, Matia Mainardis, Eleonora Pasinetti, Francesca Malpei
Publikováno v:
Resources, Conservation and Recycling. 186:106539
Autor:
Monica Fiore, Stefano Zamuner, Michela Peroni, Sofia Fernandes, Sabrina Pagliarusco, Brendan M. Johnson, Laurel M. Adams, Paolo Fina
Publikováno v:
British Journal of Clinical Pharmacology. 70:537-546
AIM To evaluate the impact of single and repeated doses casopitant on the pharmacokinetics of single dose midazolam and nifedipine (CYP3A substrates) in healthy subjects. The effect on debrisoquine metabolism (CYP2D6 substrate) was also assessed.
Autor:
Stefano, Zamuner, Brendan M, Johnson, Sabrina, Pagliarusco, Paolo, Fina, Michela, Peroni, Monica, Fiore, Laurel M, Adams, Sofia A, Fernandes
Publikováno v:
British journal of clinical pharmacology. 70(4)
To evaluate the impact of single and repeated doses casopitant on the pharmacokinetics of single dose midazolam and nifedipine (CYP3A substrates) in healthy subjects. The effect on debrisoquine metabolism (CYP2D6 substrate) was also assessed.Three op
Autor:
Sofia Fernandes, Stefano Zamuner, Brendan M. Johnson, Laurel M. Adams, Michela Peroni, Paolo Fina
Publikováno v:
Molecular Cancer Therapeutics. 8:C133-C133
Background: Clinical studies suggest that casopitant, a novel neurokinin-1 receptor antagonist in development for prevention of postoperative and chemotherapy-induced nausea and vomiting (PONV and CINV, respectively), is a mild to moderate inhibitor